Moreover, our pharmacologic results suggest that targeting the upstream AMPK/CAMKK complex may offer therapeutic benefit to KRAS/LKB1 mutant lung adenocarcinoma patients. Here, CAMKK2 is linked to lung adenocarcinoma.